trending Market Intelligence /marketintelligence/en/news-insights/trending/b37y35r9vjiogicvbm8irw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Pfizer to invest, collaborate with BioInvent International

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Pfizer to invest, collaborate with BioInvent International

Pfizer Inc. is investing $6 million in BioInvent International AB, a Swedish biotech developing treatments for cancer.

The pharma giant will purchase 21,973,594 shares representing 7.2% of the company for 2.56 Swedish kronor apiece to help the company raise funds for continued research.

Furthermore, Pfizer will pay another $4 million in early and up-front payment in exchange for the exclusive right to develop and commercialize any antibodies generated.

BioInvent can further receive over $500 million in milestone-related payments assuming that five antibodies are developed through to commercialization. The biotech company will also receive royalties on sales of any potential products that may result as a result of the collaboration.

As of Dec. 20, US$1 was equivalent to 9.37 Swedish kronor.